Business Wire

Zayed Sustainability Prize Opens Global Call for Transformative Solutions

10.2.2025 14:21:00 CET | Business Wire | Press release

Share

The US $5.9 million fund empowers small and medium sized enterprises, nonprofits, and high schools to develop sustainable solutions and transform their communitiesAcross 6 key categories – Health, Food, Energy, Water, Climate Action and Global High Schools – winners will be recognised for their groundbreaking impact and receive the prestigious award

The UAE’s Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies which has impacted 400 million lives worldwide by advancing innovative solutions to pressing global challenges, has officially announced its call for submissions for 2026. Marking 17 years of continued support and empowerment for the next generation of sustainability champions, the Prize invites small to medium enterprises (SMEs), nonprofit organisations, and high schools to submit their projects in six distinct categories: Health, Food, Energy, Water, Climate Action, and Global High Schools.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210057043/en/

Zayed Sustainability Prize Opens Global Call for Transformative Solutions (Photo: AETOSWire)

In 2024, the Prize received 5,980 submissions from 156 countries, reflecting a growing international commitment to sustainable development. As the 2026 submission cycle begins, the Prize aims to build on this momentum and seize the unique opportunity at the Nexus of Next, a dynamic convergence of technological innovation, human ingenuity, and strategic vision to accelerate progress worldwide.

Commenting on the launch, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize said: “The Zayed Sustainability Prize honours Sheikh Zayed’s vision of advancing inclusive sustainable and humanitarian development. By supporting projects that harness new technologies to improve lives and drive prosperity in local communities, the Prize places people at the heart of progress, and demonstrates the role of the Nexus of Next in accelerating socio-economic growth worldwide.”

The Prize will reward US $1 million to the winners of each organisational category, while those in the Global High Schools category - split into six world regions – can claim up to US $150,000 to deploy or further expand their project. This funding has already enabled tangible progress and improved living conditions in vulnerable areas around the world, from expanding healthcare access in Southeast Asia to reducing food poverty in Sub-Saharan Africa.

The most recent Zayed Sustainability Prize winners were recognised at an Awards Ceremony in Abu Dhabi in the presence of H.H. Sheikh Mohamed bin Zayed, President of the United Arab Emirates, alongside 11 Heads of State and several Ministers and business leaders. These distinguished guests witnessed the promise and impact of each winner, as well as the UAE’s firm commitment to providing a platform for such solutions to grow.

For the 2026 cycle, applicants in the Health, Food, Energy, Water and Climate Action categories must prove that their solution is improving access to essential services in their communities, and that they can implement a long-term vision for better living and working conditions. For the Global High Schools category, projects should be led by students and must demonstrate innovative approaches to address sustainability challenges.

To encourage a broader range of organisations and high schools to participate, the Prize accepts submissions in multiple languages, including Arabic, Chinese, English, French, Russian, Spanish, and Portuguese.

The evaluation of each submission to the Prize consists of a rigorous, three-stage process. First, due diligence is conducted on all submissions to ensure that they meet the Prize’s evaluation criteria of Impact, Innovation, and Inspiration. This identifies the qualified entries and results in the selection of eligible candidates. Following this, evaluations are undertaken by a Selection Committee consisting of category-specific panels of independent international experts. From this shortlist of candidates, the finalists are chosen and then sent to the Prize Jury who unanimously elect the winners across all six categories.

Winners of the Zayed Sustainability Prize will be announced at an Awards Ceremony in 2026.

For more details and to submit your application, please click here.

About the Zayed Sustainability Prize

The Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies, is the UAE’s pioneering award for innovative solutions to global challenges.

A tribute to the legacy and vision of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize aims to drive sustainable development worldwide.

Each year, across the Health, Food, Energy, Water, Climate Action and Global High Schools categories, the Prize rewards organisations and high schools for their groundbreaking solutions to our planet’s most pressing needs.

Through its 128 winners, in 17 years, the Prize has positively impacted over 400 million lives across the globe, inspiring innovators to amplify their impact, and chart a sustainable future for all.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210057043/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye